专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012177788A1 MODULATORS OF 4-1BB AND IMMUNE RESPONSES 审中-公开
标题翻译： 4-1BB和免疫应答的调节器
公开(公告)号：WO2012177788A1
公开(公告)日：2012-12-27
申请号：PCT/US2012/043383
申请日：2012-06-20
申请人： LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY , CROFT, Michael , MADIREDDI, Shravan
发明人： CROFT, Michael , MADIREDDI, Shravan
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/241 , A61K38/02 , A61K2039/505 , C07K16/2851 , C07K16/2878 , C07K2317/76 , C07K2319/30 , C12N15/113 , C12N15/1136 , C12N15/1138 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12N2310/3513
摘要： The invention provides peptides and fragments, methods and uses based upon modulating the binding or interaction between 4-lBB and galectins such as Galectin-9. Modulating such binding or interaction between 4- IBB and a galectin, such as Galectin 9. modulates an immune response.
摘要翻译：本发明提供了基于调节4-1BB和半乳凝素如Galectin-9之间的结合或相互作用的肽和片段，方法和用途。调节4-IBB和半乳凝素如Galectin9之间的这种结合或相互作用调节免疫应答。

2. 发明申请

WO2006063067A3 NOVEL TNF RECEPTOR REGULATORY DOMAIN 审中-公开
标题翻译：新型TNF受体调节区
公开(公告)号：WO2006063067A3
公开(公告)日：2006-11-23
申请号：PCT/US2005044296
申请日：2005-12-09
申请人： JOLLA INST ALLERGY IMMUNOLOG , CHEUNG TIMOTHY C , HUMPHREYS IAN R , POTTER KAREN G , BENEDICT CHRISTOPHER A , WARE CARL F , DE TREZ CARL , CROFT MICHAEL , KRONENBERG MITCHELL
发明人： CHEUNG TIMOTHY C , HUMPHREYS IAN R , POTTER KAREN G , BENEDICT CHRISTOPHER A , WARE CARL F , DE TREZ CARL , CROFT MICHAEL , KRONENBERG MITCHELL
IPC分类号： C07K14/705 , A61K38/17 , A61K48/00 , C07K16/28 , C12N15/62
CPC分类号： C07K14/70578 , A61K38/00 , C07K2317/00 , C07K2317/74
摘要： Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.
摘要翻译：疱疹病毒进入介质（HVEM）是肿瘤坏死因子受体超家族（TNFRSF）的成员，并且作为通过从TNF相关配体LIGHT（p30，TNFSF14）或抑制性信号传播阳性信号调节T细胞活化的分子开关通过免疫球蛋白超家族成员B和T淋巴细胞衰减（BTLA）。公开了位于HVEM的富含半胱氨酸的结构域1中的BTLA的新结合位点。 HVEM上的BTLA结合位点与单纯疱疹病毒-1包膜糖蛋白D（gD）的结合位点重叠，但不同于LIGHT结合的位置，而gD抑制两个配体的结合。存在于人巨细胞病毒中的BTLA激活蛋白被鉴定为UL144。 UL144结合BTLA，但不结合LIGHT，并抑制T细胞增殖。

3. 发明申请

WO2016022731A1 SYSTEMS AND METHODS FOR RWD APP STORE BASED COLLABORATIVE ENTERPRISE INFORMATION MANAGEMENT 审中-公开
标题翻译： RWD APP STORE基于协同企业信息管理的系统与方法
公开(公告)号：WO2016022731A1
公开(公告)日：2016-02-11
申请号：PCT/US2015/043888
申请日：2015-08-06
申请人： CROFT, Michael
发明人： CROFT, Michael
IPC分类号： G06Q50/10 , G06Q10/00
CPC分类号： H04L67/32 , G06Q10/063112 , H04L67/02 , H04L67/1097 , H04L67/125 , H04L67/22 , H04L67/306
摘要： In a collaborative information management system, a set of collaborative information management servers enables the publication of web apps and widgets that provide web app views / functionality to private libraries, public libraries, or semi-public libraries. The set of collaborative information management servers obtains business enterprise data from multiple enterprise information management systems, parses such data, and renders parsed data in a standard format usable by web apps and widgets. The set of collaborative information management servers enables user access to web apps and widgets based on user roles, which can include intra-enterprise roles for users directly employed or hired by a business enterprise as well as extra-enterprise roles for users not directly employed or hired by the business enterprise, such as suppliers, distributors, and/or customers of the business enterprise. User access to web apps can further be based on verifiable user relationships across different business enterprises.
摘要翻译：在协作信息管理系统中，一组协同信息管理服务器能够发布向私人图书馆，公共图书馆或半公共图书馆提供网络应用程序视图/功能的网络应用程序和小部件。协同信息管理服务器集合从多个企业信息管理系统获取企业数据，解析这些数据，并以Web应用程序和小部件可用的标准格式呈现分析数据。协作信息管理服务器集允许用户基于用户角色访问Web应用程序和小部件，这些用户角色可以包括直接雇用或雇用商业企业的用户的企业内角色以及未直接使用的用户的外部企业角色由商业企业雇用，如企业的供应商，经销商和/或客户。用户对Web应用程序的访问可以进一步基于不同商业企业之间可验证的用户关系。

4. 发明申请

WO2007062245A2 HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME 审中-公开
标题翻译：人类单克隆抗体人CD134（OX40）及其制备和使用方法
公开(公告)号：WO2007062245A2
公开(公告)日：2007-05-31
申请号：PCT/US2006/045522
申请日：2006-11-27
申请人： KIRIN BEER KABUSHIKI KAISHA , LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY , KATO, Shinichiro , SOLOFF NUGENT, Rachel , YOSHIDA, Hitoshi , CROFT, Michael
发明人： KATO, Shinichiro , SOLOFF NUGENT, Rachel , YOSHIDA, Hitoshi , CROFT, Michael
IPC分类号： C07K16/00
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/30 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C12N2799/026
摘要： The invention provides antibodies that specifically bind to OX40 (CD 134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
摘要翻译：本发明提供特异性结合OX40（CD134），称为OX40抗体，抗OX40或抗OX40抗体的抗体。特异性结合OX40的本发明抗体包括哺乳动物（人，灵长类动物等），人源化和嵌合抗OX40抗体。特异性结合OX40的本发明抗体和抗体子序列（片段）包括纯化和分离的抗体及其药物制剂，可用于各种方法，包括治疗，筛选和检测方法。

5. 发明申请

WO2012031892A1 MANAGING A USER INTERFACE FOR AN APPLICATION PROGRAM 审中-公开
标题翻译：管理应用程序的用户界面
公开(公告)号：WO2012031892A1
公开(公告)日：2012-03-15
申请号：PCT/EP2011/064486
申请日：2011-08-23
申请人： INTERNATIONAL BUSINESS MACHINES CORPORATION , RICE, Adam, Robert , JONES, Philip , CROFT, Michael, Robert , WHITBOURNE, Matthew
发明人： RICE, Adam, Robert , JONES, Philip , CROFT, Michael, Robert , WHITBOURNE, Matthew
IPC分类号： G06F9/44 , G06F3/048
CPC分类号： G06F3/0481 , G06F3/0482 , G06F9/453
摘要： A method, apparatus and computer program is disclosed for managing a user interface (UI) for an application program in which a plurality of user interface methods are provided for a given application program function, one or more of the more frequently used UI options being maintained in the UI while one or more of the less frequently used UI options are removed.
摘要翻译：公开了一种用于管理应用程序的用户界面（UI）的方法，装置和计算机程序，其中为给定的应用程序功能提供多个用户界面方法，一个或多个更频繁使用的UI选项被维护在UI中，而一个或多个不常用的UI选项被删除。

6. 发明申请

WO2009039310A3 LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT 审中-公开
标题翻译：哮喘，肺和气道炎症，呼吸障碍，间质性，肺炎和纤维性疾病治疗的光抑制剂
公开(公告)号：WO2009039310A3
公开(公告)日：2009-12-03
申请号：PCT/US2008076903
申请日：2008-09-18
申请人： JOLLA INST ALLERGY IMMUNOLOG , CROFT MICHAEL , DOHERTY TAYLOR , SALEK-ARDAKANI SHAHRAM
发明人： CROFT MICHAEL , DOHERTY TAYLOR , SALEK-ARDAKANI SHAHRAM
IPC分类号： A61K38/19 , A61K39/395 , A61P11/00 , G01N33/53 , G01N33/68
CPC分类号： C07K16/2875 , A61K9/007 , A61K31/00 , A61K38/191 , A61K39/3955 , A61K45/06 , A61K49/0004 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2319/70
摘要： Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder. LIGHT (p30 polypeptide) inhibitors comprise subsequences of LIGHT, LTpR (lymphotoxin beta receptor), HVEM (herpesvirus entry mediator), or antibodies binding to LIGHT (p30 polypeptide), LTpR or HVEM. Said LIGHT inhibitors are used to treat lung or airway inflammation, asthma, respiratory or interstitial or pulmonary or fibrotic diseases or disorders, like e.g. asthma or airway remodeling.
摘要翻译：提供治疗炎性疾病，疾病和病症的方法。方法包括例如将足够量的LIGHT抑制剂与受试者接触或施用以治疗炎性疾病，疾病或病症。 LIGHT（p30多肽）抑制剂包含LIGHT，LTpR（淋巴毒素β受体），HVEM（疱疹病毒进入介体）或结合LIGHT（p30多肽），LTpR或HVEM的抗体的子序列。所述LIGHT抑制剂用于治疗肺或气道炎症，哮喘，呼吸或间质或肺或纤维化疾病或疾病，例如，哮喘或气道重塑。

7. 发明申请

WO2009039310A2 LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT 审中-公开
标题翻译：哮喘，肺和气道炎症，呼吸障碍，间质性，肺炎和纤维性疾病治疗的光抑制剂
公开(公告)号：WO2009039310A2
公开(公告)日：2009-03-26
申请号：PCT/US2008/076903
申请日：2008-09-18
申请人： LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY , CROFT, Michael , DOHERTY, Taylor , SALEK-ARDAKANI, Shahram
发明人： CROFT, Michael , DOHERTY, Taylor , SALEK-ARDAKANI, Shahram
IPC分类号： A61P29/00 , A61P11/06 , A61K39/395 , A61K38/00 , A61K49/00
CPC分类号： C07K16/2875 , A61K9/007 , A61K31/00 , A61K38/191 , A61K39/3955 , A61K45/06 , A61K49/0004 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2319/70
摘要： Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.
摘要翻译：提供治疗炎性疾病，疾病和病症的方法。方法包括例如将足够量的LIGHT抑制剂与受试者接触或施用以治疗炎性疾病，疾病或病症。

8. 发明申请

WO2007062245A3 HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME 审中-公开
标题翻译：人单克隆抗体人类CD134（OX40）及其制备和使用方法
公开(公告)号：WO2007062245A3
公开(公告)日：2007-12-06
申请号：PCT/US2006045522
申请日：2006-11-27
申请人： KIRIN BREWERY , JOLLA INST ALLERGY IMMUNOLOG , KATO SHINICHIRO , SOLOFF NUGENT RACHEL , YOSHIDA HITOSHI , CROFT MICHAEL
发明人： KATO SHINICHIRO , SOLOFF NUGENT RACHEL , YOSHIDA HITOSHI , CROFT MICHAEL
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06 , C12N5/20 , C12N15/13
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/30 , C07K2317/565 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C12N2799/026
摘要： The invention provides antibodies that specifically bind to OX40 (CD 134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
摘要翻译：本发明提供了特异性结合OX40（CD134）的抗体，称为OX40抗体，抗OX40或抗OX40抗体。与OX40特异性结合的发明抗体包括哺乳动物（人，灵长类动物等），人源化和嵌合抗OX40抗体。与OX40特异性结合的发明抗体和抗体子序列（片段）包括纯化和分离的抗体及其药物制剂，可用于各种方法，包括治疗，筛选和检测方法。

9. 发明申请

WO2006063067A9 NOVEL TNF RECEPTOR REGULATORY DOMAIN 审中-公开
标题翻译：新的TNF受体调节域
公开(公告)号：WO2006063067A9
公开(公告)日：2006-10-05
申请号：PCT/US2005044296
申请日：2005-12-09
申请人： JOLLA INST ALLERGY IMMUNOLOG , CHEUNG TIMOTHY C , HUMPHREYS IAN R , POTTER KAREN G , BENEDICT CHRISTOPHER A , WARE CARL F , DE TREZ CARL , CROFT MICHAEL , KRONENBERG MITCHELL
发明人： CHEUNG TIMOTHY C , HUMPHREYS IAN R , POTTER KAREN G , BENEDICT CHRISTOPHER A , WARE CARL F , DE TREZ CARL , CROFT MICHAEL , KRONENBERG MITCHELL
CPC分类号： C07K14/70578 , A61K38/00 , C07K2317/00 , C07K2317/74
摘要： Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.
摘要翻译：疱疹病毒进入介质（HVEM）是肿瘤坏死因子受体超家族（TNFRSF）的成员并且充当通过从TNF相关配体LIGHT（p30，TNFSF14）或抑制性信号传播阳性信号来调节T细胞活化的分子开关通过免疫球蛋白超家族成员B和T淋巴细胞衰减剂（BTLA）。公开了位于HVEM的富半胱氨酸结构域-1的BTLA的新颖结合位点。 HVEM上的BTLA结合位点与单纯疱疹病毒-1包膜糖蛋白D（gD）的结合位点重叠，但不同于LIGHT结合的位置，但gD抑制两种配体的结合。存在于人巨细胞病毒中的BTLA活化蛋白被鉴定为UL144。 UL144结合BTLA，但不结合LIGHT，并抑制T细胞增殖。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式